Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Dose-finding Trial to Explore Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 3706674 Given Orally as Monotherapy in Patients With Unresectable Metastatic KRAS Wild Type Amplified Gastric, Oesophageal, and Gastroesophagealjunction Adenocarcinoma

NCT06056024 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06056024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06056024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Dose-finding Trial to Explore Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 3706674 Given Orally as Monotherapy in Patients With Unresectable Metastatic KRAS Wild Type Amplified Gastric, Oesophageal, and Gastroesophagealjunction Adenocarcinoma
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
December 6, 2023
Completion date
December 17, 2025
Enrollment
47 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, kras mutation